Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study

Duorui Nie¹, Qingxia Lan²,³, Yue Huang²,³, Chongkai Fang²,³, Yang Cao²* and Yao Chen²*

Abstract

Background: Pancreatic signet ring cell carcinoma (PSRCC) is a rare tumour subtype with poorly understood epidemiological characteristics and prognosis. We attempted to comprehensively characterise the epidemiology and survival outcomes of PSRCC.

Methods: Patients diagnosed with PSRCC between 2000 and 2018 were identified using Surveillance, Epidemiology and End Results Stat 8.3.9.2 software. Age-adjusted incidence and survival were calculated. Survival curves were plotted using the Kaplan–Meier method, and the differences between survival curves were compared using the log-rank test. Cox proportional hazards models were used to evaluate factors that independently predict overall survival. The primary analysis was a complete case analysis; multiple imputations were employed in a sensitivity analysis.

Results: We identified 585 eligible patients with PSRCC. The overall annual incidence from 2000 to 2018 was 0.349 (95% CI, 0.321–0.379) per million population. The incidence increased significantly in patients over 55 years of age and peaked at about 80 years of age (2.12 per million). Males and Black patients had the highest incidence. The observed survival rates at 1, 2 and 5 years were 20.1, 8.3 and 3.4%, respectively. Survival analysis revealed that primary surgery and chemotherapy are effective treatments for patients with PSRCC (P < 0.05). According to multivariate Cox regression analysis, early stage and receiving surgery and chemotherapy were favourable factors (P < 0.05). Similar conclusions were drawn from the interpolated data.

Conclusions: PSRCC is a highly malignant tumour that predominate in elderly, male and Black patients. The prognosis is poor with a 5-year survival rate of 3.4%; however, multivariate analysis and adjusted models accounting for missing data revealed that early diagnosis, surgery and chemotherapy are effective in improving the prognosis.

Keywords: Epidemiology, Pancreatic signet ring cell cancer, SEER database, Survival analysis

Introduction

Signet ring cell carcinoma (SRCC) is a rare histological type of adenocarcinomas in which the nucleus is squeezed sideways to form a “signet ring” appearance owing to the intra-cytoplasmic mucin vacuoles containing more than 50% of the mucin protein [1]. Over 96% of SRCC cases originate in the stomach, with the remaining cases originating in the rectum, gallbladder, colon, breast, bladder and pancreas [2]. Pancreatic signet ring cell carcinoma (PSRCC) is a very rare tumour occurring in less than 1% of pancreatic carcinoma [3]. Diagnosis of primary PSRCC requires a tumour with at least 50% signet ring cell morphology and the exclusion of metastases from other sites [1, 4]. Patients with pancreatic cancer...
without obvious clinical symptoms are frequently not diagnosed until the tumour is at an advanced stage. This applies to PSRCC, which has a reported first-visit metastasis rate of 69.4%, contributing to its poor prognosis. Furthermore, the ease of invasion of surrounding tissues and metastasis contribute to the poor prognosis [5]. In addition to these properties of PSRCC, no standard therapy has been established. The value of chemotherapy has been debated. Although SRCC is generally considered to be insensitive to chemotherapy, Radojkovic et al. [6] reported a case of a patient with PSRCC who responded effectively to gemcitabine neoadjuvant chemotherapy. Furthermore, there is controversy surrounding the benefits of surgery and radiation.

Owing to the rare nature of PSRCC, it hinders our understanding of the clinical features and treatment of PSRCC. To our knowledge, three large studies of PSRCC were based on data from the US Surveillance, Epidemiology and End Results (SEER) registry. Patel reported the epidemiological factors and treatment effects on 497 patients with PSRCC diagnosed between 1985 and 2013 [7]. Although this study is the most detailed description of PSRCC, it did not exclude patients with non-pathological diagnoses, and it also lacked information about chemotherapy and failed to measure its value. Furthermore, the impact of surgery and radiotherapy in each stage was also unknown, and the study did not describe the age-adjusted incidence of PSRCC. The other two studies involving PSRCC evaluated the effect of primary tumour location on survival of SRCC [8] and reported the trends of incidence and survival in patients with gastroenteropancreatic [9]. Although both studies included some of the clinical features of PSRCC, a detailed description or analysis of its incidence, characteristics, prognostic factors and treatment methods were not provided. Importantly, the role of chemotherapy has not yet been elucidated.

Therefore, to describe the clinical characteristics of PSRCC in more detail, we conducted this study: (1) to determine the epidemiological characteristics of the patients, such as determining a more accurate age-adjusted incidence and calculating age-adjusted mortality for the first time (2) to clarify the prognostic impact of surgery, radiotherapy and chemotherapy in each summary stage and (3) to ascertain the prognostic impact of chemotherapy on overall survival (OS).

**Patients and methods**

**Study population**

The SEER database collects information on tumour clinicopathological, treatment and vital status from population-based cancer registries covering approximately 27.8% of the U.S. population (https://seer.cancer.gov). This study does not require Institutional Review Board approval since the SEER study data is available to the public, and we have access to the study data under a SEER license (Login number: 13487-NOV2020). Furthermore, we declared all methods were performed per relevant guidelines and regulations.

“The SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000–2018)” was used to calculate the incidence, demographic and clinicopathologic characteristics and survival. Patients with only one primary PSRCC diagnosed between 2000 and 2018 by pathologically confirmation were selected. All populations were used for incidence calculations; however, when survival analysis was performed those with unknown follow-up time and age were not included. The cohort for survival analysis included 585 patients with PSRCC who met the inclusion criteria.

**Definition of variables**

The following variables were extracted from the SEER database: age at diagnosis (≤67 and >67), gender (male and female), marital status (married or unmarried and unknown), race (White, Black and others [American Indian/AK Native and Asian/Pacific Islander]), year of diagnosis (2000–2009 and 2010–2018), regional nodes positive (negative, positive and no nodes examined), tumour size (≤4 cm and >4 cm), primary tumour location (head, body, tail and other), summary stage (localised, regional and distant), differentiation grade (I/II and III/IV), primary surgery (yes or no), radiation (yes or no/unknown), chemotherapy (yes or no/unknown), vital status and survival months. Age at diagnosis was converted to binary data by using a median cut-off value of 67. American Indian/AK Native and Asian/Pacific Islander were classified as “Others”. “C25.3-Pancreatic Duct”, “C25.7-Other specified parts of Pancreas” and “C25.4-Islets of Langerhans” were classified as “Others”. Consequently, the primary sites were grouped by “Head”, “Body”, “Tail”, “Other” and “non-otherwise specified (NOS)”. The staging data were based on the SEER Summary Stage 2000, which categorises the disease’s extent as “localised”, “regional” or “distant” [10]. A localised disease is defined as a tumour localised to the pancreas. The regional disease involves tumours of the pancreas extending to adjacent organs, regional lymph nodes or both. A distant disease is defined as those who had distant metastases at the time of diagnosis.

Survival months were defined as the length of time from the month of initial diagnosis to the patient’s death from any cause or the last month of follow-up (November 2020). The primary outcome was OS, which was defined as an all-cause of death. Furthermore, survival rates were estimated using the observed survival, expected
and relative survival rates with age adjustment [11, 12]. Expected survival rates are calculated for individual years relative to the standard population of the United States (U.S.) 1992–2006. Relative survival was defined as observed survival as a percentage of expected survival.

Statistics analysis
Using SEER*Stat software, age-adjusted incidence trends were estimated and adjusted for the 2000 U.S. standard population, as well as observed, relative and expected survival. Classification variables were expressed as frequency and percentage, whereas continuity variables were expressed as quartiles. The Kaplan–Meier method was used to plot survival curves, and the log-rank test was performed to assess the differences between the survival curves. Univariate and subsequent multivariate Cox regression analyses were performed to evaluate factors that have independent predictive effects on the OS and calculate hazard ratios (HRs) and 95% confidence intervals (CIs).

We used multiple imputation (MI) replicates adjusted for Cox analysis to perform a sensitivity analysis since our dataset contained missing values [13, 14]. The original data, as they were retrieved from the database, were introduced as the first model was built. Following imputation analysis, the pooled data were introduced in a new Cox regression model using the same covariates. Statistical analysis was performed with R 4.0.4 (http://www.r-project.org/) and GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com), and \( P < 0.05 \) was considered statistically significant.

Results

Demographic and clinicopathologic characteristics
In this study, a total of 585 eligible patients with PSRCC were identified. The clinical features of the patients are presented in Table 1. The median age was 67 years. The male-to-female ratio in this study was 1.25:1, with 325 (55.6%) male patients and 260 (44.4%) female patients. White patients account for 82.7% of the population. Of 585 patients, 383 (65.5%) patients had a record of available tumour size. Among the known records, 43.6% of the tumours were >4 cm and 56.4% were ≤4 cm. The most common grade of differentiation was III/IV, accounting for 87.9%, while grade I/II accounted for 12.1%.

At diagnosis, 70% of patients had distant metastatic disease. Chemotherapy, which accounts for 45% of PSRCC treatment, is the initial treatment option for patients. One hundred (17.2%) patients underwent surgery, while 80 (13.7%) patients received radiation therapy. When presented in summary stages, details of treatment are presented in Table 2. Of 170 patients with localised/regional disease, 78 (45.9%) underwent primary surgery, 87 (51.2%) received chemotherapy and 54 (31.8%) received radiotherapy.

| Variables                          | Available data-N (%) | N (%)  |
|------------------------------------|----------------------|--------|
| **Age at diagnosis**               |                      |        |
| 67.0 [59.0, 75.0]                  |                      |        |
| < =67                              | 300 (51.3)           |        |
| > 67                               | 285 (48.7)           |        |
| **Sex**                            |                      |        |
| Female                             | 260 (44.4)           |        |
| Male                               | 325 (55.6)           |        |
| **Race**                           |                      |        |
| White                              | 482 (82.7)           |        |
| Black                              | 62 (10.6)            |        |
| Other                              | 39 (6.7)             |        |
| **Year of diagnosis**              |                      |        |
| 2000–2009                          | 323 (55.2)           |        |
| 2010–2018                          | 262 (44.8)           |        |
| **Marital status at diagnosis**    |                      |        |
| Married                            | 331 (59.1)           |        |
| Unmarried                          | 229 (40.9)           |        |
| **Differentiation grade**          |                      |        |
| I/II                               | 34 (12.1)            |        |
| III/IV                             | 246 (87.9)           |        |
| **Tumor size**                     |                      |        |
| < =4                               | 216 (56.4)           |        |
| > 4                                | 167 (43.6)           |        |
| **Primary site**                   |                      |        |
| Head                               | 273 (46.7)           |        |
| Body                               | 60 (10.3)            |        |
| Tail                               | 85 (14.5)            |        |
| Other                              | 44 (7.5)             |        |
| **Regional nodes status**          |                      |        |
| Negative                           | 41 (7.1)             |        |
| Positive                           | 88 (15.2)            |        |
| No nodes examined                  | 449 (77.7)           |        |
| **Summary stage**                  |                      |        |
| Localized/Regional                 | 170 (30.0)           |        |
| Distant                            | 396 (70.0)           |        |
| **Surgery**                        |                      |        |
| Yes                                | 100 (17.2)           |        |
| No                                 | 481 (82.8)           |        |
| **Chemotherapy**                   |                      |        |
| Yes                                | 263 (45.0)           |        |
| No/Unknown                         | 322 (55.0)           |        |
| **Radiation**                      |                      |        |
| Yes                                | 80 (13.7)            |        |
| No/Unknown                         | 505 (86.3)           |        |
Table 2 The clinical features of the patients with pancreatic signet ring cell carcinoma (PSRCC) according to stratification by summary stage

| Therapy          | Levels | Distant | Localised/Regional |
|------------------|--------|---------|--------------------|
| Surgery (%)      | No     | 374 (94.7) | 92 (54.1)         |
|                  | Yes    | 21 (5.3)  | 78 (45.9)         |
| Chemotherapy (%) | No/Unknown | 224 (56.6) | 83 (48.8)         |
|                  | Yes    | 172 (43.4) | 87 (51.2)         |
| Radiation (%)    | No/Unknown | 371 (93.7) | 116 (68.2)        |
|                  | Yes    | 25 (6.3)  | 54 (31.8)         |

Age-adjusted incidence

Table 3 summarises the age-adjusted incidence rates for common clinical features. The overall annual incidence of PSRCC within the SEER-18 database was 0.349 (95% CI, 0.321–0.379) per million population between 2000 and 2018. The age-adjusted incidence rates are higher in men than in women, higher in Black patients than in other races and tumours in the head of the pancreas are more common between 2000 and 2009. As presented in Fig. 1, the annual adjusted incidence rate decreased with time, from 0.48 per million in 2000 to 0.16 per million in 2018. Over the past few decades, there has been a significant decline in the incidence of PSRCC. The incidence of PSRCC increased significantly with age, especially in patients aged 55 and above, and gradually reduced after 70 years of age, peaked between the ages 75 and 79 years (2.12 per million) and gradually declined thereafter (Fig. 2). Similar results were observed when the incidence was grouped by sex (Fig. 3a). The changes in incidence rates by age across ethnic groups are presented in Fig. 3b. The incidence peaked earlier in Black patients than in White patients, with the first peak occurring between the ages of 65 and 69 for Black patients in a bimodal distribution and between the ages 75 and 79 for White patients. The incidence rate of Black patients was higher than that of other races (0.369 per million).

Survival analysis

Subsequently, the age-adjusted survival rate was calculated using SEER*Stat software version 8.3.9 and is presented in Table 4. The 1-, 2- and 5-year observed survival rates were 20.1, 8.3 and 3.4%, respectively. The log-rank test revealed that there may be a relationship between OS and the variables age at diagnosis (Fig. 4a), year of diagnosis (Fig. 4b), marital status (Fig. 4c), primary site (Fig. 4d), differentiation grade (Fig. 4e), summary stage (Fig. 4f), regional nodes status (Fig. 4g), tumour size (Fig. 4h), surgery (Fig. 4i), chemotherapy (Fig. 4j) and radiation (Fig. 4k). The stage has a great impact on the course of treatment. Therefore, the effectiveness of treatment in different summary stages was compared. The Kaplan–Meier survival curve stratified according to the therapy and summary stage are displayed in Fig. 5. Patients who underwent primary tumour surgery, chemotherapy and radiation had substantially improved OS (Fig. 5, P < 0.05).

Specifically, compared with the reference group in univariate Cox analysis (Table 5), patients with older age (HR, 1.27; 95% CI, 1.07–1.50; P = 0.005), unmarried (HR, 1.31; 95% CI, 1.10–1.56; P = 0.002), grade III/IV disease
(HR, 1.84; 95% CI, 1.25–2.72; \( P = 0.002 \)), tumours not at the head of the pancreas (Body: HR, 1.47; 95% CI, 1.10–1.97; \( P = 0.009 \), Tail: HR, 1.29; 95% CI, 1.00–1.66; \( P = 0.048 \), Other: HR, 1.39; 95% CI, 1.01–1.93; \( P = 0.045 \)) and larger tumour size (HR, 1.37; 95% CI, 1.11–1.69; \( P = 0.003 \)) were associated with poor prognosis (HR > 1, \( P < 0.05 \)). When these factors were incorporated in multivariate Cox regression, it was indicated that the summary stage, regional nodes status, surgery and chemotherapy were independent factors for patients with PSRCC.

Multiple imputation (MI) and sensitivity analysis
MI procedures were applied to account for missing data of some key variables in our study, and the results are presented in supplementary Table 1. Receiving surgery (HR, 0.40; 95% CI, 0.26–0.61; \( P < 0.001 \)), chemotherapy (HR, 0.36; 95% CI, 0.30–0.44; \( P < 0.001 \)), and an early stage at diagnosis (summary stage: localised/regional, HR, 0.62; 95% CI, 0.49–0.79; \( P < 0.001 \); regional nodes status: negative, HR, 0.65; 95% CI, 0.42–0.99; \( P = 0.046 \)) remained associated with a better prognosis in multivariate Cox regression following MI. The most recent year of diagnosis (HR, 0.741; 95% CI, 0.619–0.886; \( P < 0.001 \)) was also associated with a better prognosis, while unmarried patients (HR, 1.322; 95% CI, 1.092–1.601; \( P = 0.005 \)) and older years (HR, 0.74; 95% CI, 0.62–0.89; \( P = 0.048 \)) were associated with a worse prognosis.

Discussion
Due to its rarity, the studies on PSRCC were case reports, and three large studies were based on SEER registries. The published literature on PSRCC is reviewed in Table 6. Three of them, Wu et al. [8], Li et al. [9] and Patel et al. [7] described the clinical characteristics of PSRCC. Overall, our study provides comprehensive information on the incidence, clinical features, treatment and prognosis of patients with PSRCC.

The age-adjusted annual incidence of PSRCC was 0.349 per million population in the U.S. According to Li et al. [9], between 2000 and 2014, the age-adjusted incidence of PSRCC marginally decreased. Similar findings were observed in our study; however, we described the incidence of PSRCC in more detail. The incidence decreased from 0.48 to 0.16 per million between 2000 to 2018. Although the reasons for the decline are unclear, we speculate that it may be owing to the advancements in diagnostic techniques that can more accurately distinguish tumours similar to PSRCC [18, 23], resulting in a decrease in the incidence of PSRCC. Moreover, we observed that the incidence of PSRCC increased significantly in patients over 55 years of age, gradually decreased after 70 years of age, peaked at about 80 years of age (2.12 per million) and gradually decreased thereafter. Therefore, the differential diagnosis of PSRCC in individuals over 55 years of age requires greater focus. In addition, the peak age of onset varies amongst ethnic
groups. It suggests that different ethnic groups have different concerns.

The demographics of PSRCC in the U.S. described in this study are comparable to those previously reported, with the average age reported in most SEER-based studies being approximately 67 years old. All studies reported male prevalence of 52.6–55.6%, and in our study, the male prevalence in PSRCC was 55.6%. Compared with the other three studies, we additional reported the marital status of PSRCC and observed that most patients were married. The addition of lymph node metastasis and tumour size enhanced our understanding of the clinicopathological features of PSRCC.

Age, primary site, grade, summary stage and local treatment have been previously demonstrated to be independent prognostic factors of OS in univariate Cox regression analysis [7]. However, previous studies lacked crucial information, such as marital status, regional nodes status and chemotherapy, and failed to assess their impact on OS. Our study indicated that chemotherapy can also significantly affect OS. Subsequent multivariate Cox analysis revealed that summary stage, regional nodes status, surgery and chemotherapy can significantly affect OS in both complete case and MI analyses. In addition, the stage at diagnosis is significantly correlated with prognosis, and the late stage is associated with poor prognosis, suggesting that early and timely diagnosis is also an effective measure to improve the prognosis of patients.

PSRCC is a rare disease, thus, limited investigations have been performed on it. Clinically, the therapy method of PSRCC is mostly referred to as pancreatic ductal adenocarcinoma. Surgery is usually recommended for non-metastatic PSRCC, while chemotherapy is the primary treatment option for metastatic PSRCC. In this study, the survival curve of the treatment mode was stratified based on the summary stage. We observed that surgery for primary tumours not only significantly improved OS at localised/regional stages but also distant stages. Indeed, tumour resection remains the only way to cure and is usually the preferred treatment for resectable or locally advanced pancreatic tumours [19]. However, it remains unclear how surgery can affect PSRCC metastases. Previous studies have shown that primary surgery can improve the OS of patients with metastatic pancreatic cancer [24, 25]. As a variant of adenocarcinoma, surgery may be a potential treatment option for patients with metastatic PSRCC, and this possibility is even greater owing to improvements in neoadjuvant chemotherapy [6].

Table 4 Observed, expected and relative survival rates of pancreatic signet ring cell carcinoma (PSRCC) patients from 2000 to 2018

| Years | Observed survival (SE) | Expected survival (SE) | Relative survival (SE) |
|-------|------------------------|------------------------|------------------------|
| 1     | 20.1% (1.7%)           | 97.50%                 | 20.5% (1.7%)           |
| 2     | 8.30% (1.2%)           | 94.90%                 | 8.70% (1.2%)           |
| 3     | 5.30% (1.0%)           | 92.40%                 | 5.60% (1.0%)           |
| 4     | 3.80% (0.8%)           | 89.50%                 | 4.10% (0.9%)           |
| 5     | 3.40% (0.8%)           | 86.60%                 | 3.70% (0.9%)           |

Fig. 3 The age-stratified incidence rates for different races and genders
Similarly, previous research lacked information about chemotherapy and failed to assess the value of chemotherapy for PSRCC. Our findings disprove the preconceived notion that gastric SRCC types are insensitive to chemotherapy and demonstrate that chemotherapy is an independent prognostic factor [26]. These findings further illustrate the importance of chemotherapy in the prognosis of PSRCC. To our surprise, radiotherapy is not an independent predictor of OS, and it was unclear whether it is due to the statistical failure to meet the criterion imposed by the sample size limit or caused by a special entity. However, as a local treatment method, radiotherapy has been proven to improve local control [27].

In sensitivity analysis, unmarried patients had a worse prognosis. The important role of marital status in pancreatic cancer is increasingly recognised [28–30] and has also been reported in subtypes of pancreatic ductal adenocarcinoma [31, 32]. However, the underlying mechanisms associated with marital status and survival can be multiple and complex, it may be associated with positive facilitation in marriage, such as better health habits, psychosocial support and greater financial resources. Older age was
also associated with a worse prognosis. In addition, the most recent year of diagnosis was associated with a better prognosis. Since there have been advances over time regarding diagnostic and therapeutic approaches, especially the popularisation of multidrug chemotherapy regimens in 2011, which has improved the prognosis [33, 34]. The upper limit of the proportion of tumours that may be accurately estimated using this technique is reached when estimating the tumour grade, tumour size and primary tumour location. Therefore, rather than performing a primary analysis, a sensitivity analysis using MI data was performed. Inconsistencies in the interpolated data need to be interpreted with caution.

Although the SEER database provides us with a larger cohort to study the clinical characteristics of PSRCC,
### Table 5  
Univariate and multivariate regression analysis of overall survival (OS) in patients with pancreatic signet ring cell carcinoma (PSRCC)

| Variables                  | Levels | Univariate HR (95% CI) | Multivariate HR (95% CI) | P-value | P-value |
|----------------------------|--------|------------------------|--------------------------|---------|---------|
| Age at diagnosis           | <=67   | 1                      | 1                        |         |         |
|                            | > 67   | 1.27 (1.07–1.50)       | 1.22 (0.87–1.71)         | 0.005   | 0.244   |
| Sex                       | Female | 1                      | 1                        |         |         |
|                            | Male   | 1.04 (0.84–1.18)       | 1.02 (0.71–1.32)         |         |         |
| Race                      | Black  | 1.15 (0.76–1.73)       | 0.507                    |         |         |
|                            | Other  | 0.93 (0.71–1.23)       | 0.616                    |         |         |
| Year of diagnosis          | 2000–2009 | 1                     | 1                        |         |         |
|                            | 2010–2018 | 0.80 (0.67–0.95)       | 0.71 (0.50–1.00)         | 0.009   | 0.052   |
| Marital status at diagnosis| Married | 1                      | 1                        |         |         |
|                            | Unmarried | 1.31 (1.10–1.56)       | 1.32 (0.93–1.86)         | 0.002   | 0.120   |
| Differentiation grade      | I/II   | 1                      | 1                        |         |         |
|                            | III/IV | 1.84 (1.25–2.72)       | 1.41 (0.85–2.35)         | 0.002   | 0.183   |
| Tumour size                | <=4    | 1                      | 1                        |         |         |
|                            | > 4    | 1.37 (1.11–1.69)       | 1.02 (0.72–1.45)         | 0.003   | 0.913   |
| Primary site               | Head   | 1                      | 1                        |         |         |
|                            | Body   | 1.47 (1.10–1.97)       | 1.38 (0.78–2.43)         | 0.009   | 0.272   |
|                            | Tail   | 1.29 (1.00–1.66)       | 1.45 (0.88–2.38)         | 0.048   | 0.140   |
|                            | Other  | 1.39 (1.01–1.93)       | 1.27 (0.72–2.22)         | 0.045   | 0.412   |
| Regional nodes status      | Positive | 1                     | 1                        |         |         |
|                            | Negative | 0.71 (0.48–1.06)       | 0.58 (0.35–0.95)         | 0.97    | 0.031   |
|                            | No nodes examined | 2.53 (1.98–3.24) | 0.74 (0.53–1.07) | <0.001 | 0.040   |
| Summary stage              | Distant | 1                      | 1                        |         |         |
|                            | Localised/Regional | 0.44 (0.36–0.53) | 0.66 (0.45–0.97) | <0.001 | 0.034   |
| Surgery                    | No      | 1                      | 1                        |         |         |
|                            | Yes     | 0.31 (0.24–0.40)       | 0.30 (0.14–0.65)         | <0.001  | 0.002   |
| Chemotherapy               | No/Unknown | 1                    | 1                        |         |         |
|                            | Yes     | 0.41 (0.35–0.49)       | 0.42 (0.28–0.63)         | <0.001  |         |
| Radiation                  | No/Unknown | 1                    | 1                        |         |         |
|                            | Yes     | 0.45 (0.35–0.58)       | 1.07 (0.66–1.74)         | <0.001  | 0.782   |

Statistically significant variables are highlighted in bold

### Table 6  
Summary of studies on pancreatic signet ring cell carcinoma (PSRCC)

| First Auth | Year of publication | Data Source | Years of diagnosis | N  | Male (%) | Mean Age |
|------------|---------------------|-------------|--------------------|----|----------|----------|
| Sangang W  | 2017                | SEER database | 1988–2012          | 441| 232 (52.6)| /        |
| Hui Li     | 2019                | SEER database | 2000–2014          | 593| 330 (55.6)| 67.4     |
| Mausam Patel [7] | 2018              | SEER database | 1985–2013          | 497| 271 (54.5)| 66.6     |
| Tracey [7], Chow [15], McArthur [16], Marcy [17], Terada [18], Karaahmet [19], Nauta [20], Radojkovic [6], Yepuri [21], Alexander [3], Campbell [22] | 1984–2020 | Case reports | 1984–2020 | 11 | 6 (54.5) | 66.8     |
some limitations are also worth noting. Firstly, our study is a retrospective study, which may have selection bias and recall bias. Secondly, some valuable information is limited, such as the patient’s physical condition, comorbidities and specific treatment information, making the impact of these variables on survival difficult to assess and control. In addition, although the efficacy of chemotherapy was well validated, patients with unknown chemotherapy data were assigned to the “no/unknown” category, which in reality included those who received chemotherapy. Therefore, the trends we report may underestimate the actual rates due to misclassification. Finally, although we performed MI on the dataset and performed a master analysis and sensitivity validation of our analysis, discarding cases with missing values or performing separate analyses for cases with and without a complete dataset would have introduced a strong selection bias. Hence, to verify our findings in the future, more comprehensive data will be required.

In conclusion, PSRCC is a highly malignant tumour that predominates in elderly, male and Black patients. Approximately 70% of patients with PSRCC had distant metastasis at diagnosis, and the overall prognosis was poor. The 1-, 2- and 5-year observed survival rates were only 3.4, 8.3 and 20.1%, respectively. Timely diagnosis, surgery and chemotherapy are effective at improving the prognosis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02543-z.

Acknowledgements
We would like to thank the staff of SEER Database for their contribution in collecting and collating the information. In addition, we thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript.

Ethics disclosure
The study used de-identified data and adhered to the World Medical Association’s Declaration of Helsinki for Ethical Human Research.

Authors’ contributions
Yao Chen, Duorui Nie designed the study, Qinxia Lan, Yue Huang and Chongkai Fang performed data analysis and charting, Duorui Nie wrote the main manuscript; All authors finally revised and reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding
The study was not funded.

Availability of data and materials
Data for this study are available from the Surveillance Research Program, National Cancer Institute SEER® Stat software (www.seer.cancer.gov) version 8.4.0. Detailed steps can be obtained by referring to the inclusion and exclusion criteria in the methodology.

Declarations

Ethics approval and consent to participate
NA.

Consent for publication
NA.

Competing interests
The authors declare no conflicts of interest.

Author details
1Graduate School, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China. 2Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China. 3First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China.

Received: 9 July 2022 Accepted: 18 October 2022
Published online: 16 November 2022

References
1. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Wasington KM, Carneiro F, Cree IA. Board WHOCoTE: the 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.
2. Lee NK, Kim S, Kim HS, Jeon TY, Kim GH, Kim DU, Park DY, Kim TU, Kang DH. Spectrum of mucin-producing neoplastic conditions of the abdomen and pelvic; cross-sectional imaging evaluation. World J Gastroenterol. 2011;17(43):4757–71.
3. Alexander D, Rashid L, Hollis M, Kavuturu S. Primary signet ring cell carcinoma of the pancreatic head: a case report. Clin Case Rep. 2019;7(11):2235–8.
4. Hamilton LE, Jones K, Church N, Medlicott S. Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma: a case report of a novel association and review of the literature. BMC Gastroenterol. 2013;13:114.
5. Fukui Y. Mechanisms behind signet ring cell carcinoma formation. Biochem Biophys Res Commun. 2014;450(4):1231–3.
6. Radiokovic M, Ilic D, Ilic I. Primary signet ring cell carcinoma of the pancreas with a good response to chemotherapy: case report and literature review. Tumori. 2017;103(Suppl. 1):e50–2.
7. Patel M, Hans HS, Pan K, Khan H, Donath E, Caldera H. The impact of epidemiological factors and treatment interventions on survival in patients with signet ring cell carcinoma of the pancreas. Am J Clin Oncol. 2018;41(12):1176–84.
8. Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY, Pei XQ, Lin Q. Survival in signet ring cell carcinoma varies based on primary tumor location: a surveillance, epidemiology, and end results database analysis. Expert Rev Gastroenterol Hepatol. 2018;12(2):209–14.
9. Li H, Zong Z, Zhou T, Sun L, Wang A, Zhang Y, Ji C. Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the surveillance, epidemiology, and end results program. J Gastrointest Oncol. 2019;10(5):579–88.
10. RuHLJCC, Schussler N, editors. Summary stage 2018: codes and coding instructions. Bethesda: National Cancer Institute; 2021.
11. Zacharia BE, Bruce SS, Goldstein H, Malone HR, Neugut AI, Bruce JN. Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro-Oncology. 2012;14(8):1070–8.
12. Brown CC. The statistical comparison of relative survival rates. Biometrics. 1983;39(4):941–8.
13. Kontopantelis E, White IR, Sperrin M, Buchan I. Outcome-sensitive multiple imputation: a simulation study. BMC Med Res Methodol. 2017;17(1):2.
14. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99.
15. Chow LT, Chow WH. Signet-ring mucinous adenocarcinoma of the pancreas. Chin Med Sci J. 1994;9(3):176–8.
16. McArthur CP, Fiorella R, Saran BM. Rare primary signet ring carcinoma of the pancreas. Mo Med. 1995;92(6):298–302.
17. Marcy M, Chetaille B, Charaf-Jauffret E, Giovannini M, Delpero JR, Monges G. Signet ring cell carcinoma of the pancreas: a case report. Ann Pathol. 2002;22(4):314–6.
18. Terada T. Primary signet-ring cell carcinoma of the pancreas diagnosed by endoscopic retrograde pancreatic duct biopsy: a case report with an immunohistochemical study. Endoscopy. 2012;44(Suppl 2 UCTN):E141–2.
19. Karahmet F, Basar O, Coban S, Aydog G, Yuksel O. Signet ring cell carcinoma of both colon and pancreas. J Gastrointest Cancer. 2015;46(4):445–6.
20. Nauta S, Knoester I, van Zanten M, van Geenen E. A patient with signet ring cell carcinoma of the pancreas with a prolonged course: a case report. JOP. 2016;17:313–5.
21. Yepuri N, Naous R, Richards C, Dhir M, Jain A. Poorly differentiated signet ring cell carcinoma of pancreas masquerading as chronic pancreatitis. J Surg Case Rep. 2018;2018(8):rjy218.
22. Campbell DJ, Ioch EL, Kozak GM, Yeo CJ. Primary pancreatic signet ring cell carcinoma: a case report and review of the literature. J Pancreat Cancer. 2021;7(1):1–7.
23. El Hussein S, Khader SN. Primary signet ring cell carcinoma of the pancreas: cytopathology review of a rare entity. Diagn Cytopathol. 2019;47(12):1314–20.
24. Wang L, Yang L, Chen L, Chen Z. Do patients diagnosed with metastatic pancreatic cancer benefit from primary tumor surgery? A propensity-adjusted, population-based surveillance, epidemiology and end results (SEER) analysis. Med Sci Monit. 2019;25:2230–41.
25. Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res. 2017;9:471–9.
26. Perrot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428–38.
27. Landau E, Kalnicki S. The evolving role of radiation in pancreatic cancer. Surg Clin North Am. 2018;98(1):113–25.
28. Baine M, Sahak F, Lin C, Chakraborty S, Lyden E, Batra SK. Marital status and survival in pancreatic cancer patients: a SEER based analysis. PloS One. 2011;6(6):e21052.
29. Reyngold M, Winter KA, Regine WF, Abrams RA, Safran H, Hoffman JP, Mowat RB, Hayes JP, Kessel IL, DiPetrillo T, et al. Determination of the current role of radiation in patients with resectable pancreatic cancer: results of an ancillary analysis of NRG oncology/RTOG 9704. Oncologist. 2020;25(3):e477–83.
30. Chen ZH, Yang KB, Zhang YZ, Wu CF, Wen DW, Wu JW, Zhu GL, Du XJ, Chen L, Zhou GQ, et al. Assessment of modifiable factors for the association of marital status with cancer-specific survival. JAMA Netw Open. 2021;4(5):e2111813.
31. Duorui N, Shi B, Zhang T, Chen C, Fang C, Yue Z, Wu P, Wu Z, Huang X, Li M. The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: a population-based study. PloS One. 2020;15(12):e0243164.
32. Wu JY, Wang YF, Ma H, Li SS, Miao HL. Nomograms predicting long-term survival in patients with invasive intraductal papillary mucinous neoplasms of the pancreas: a population-based study. World J Gastroenterol. 2020;26(5):535–49.
33. Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;365(8):768–9 author reply 769.
34. Von Hoff DD, Ervin T, Arena FP, Chioeun EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma-WW, Saleh MH, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.